Comparative Pharmacology
Head-to-head clinical analysis: METRA versus METRETON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METRA versus METRETON.
METRA vs METRETON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Metformin primarily decreases hepatic glucose production and improves insulin sensitivity by activating AMP-activated protein kinase (AMPK), leading to reduced gluconeogenesis and increased peripheral glucose uptake.
Antihistamine and mast cell stabilizer. Competitively inhibits histamine at H1 receptors and prevents release of histamine and other mediators from mast cells.
Adults: 20 mg orally once daily.
1-2 mg/kg intramuscularly or intravenously every 6-8 hours as needed; maximum 100 mg per dose.
None Documented
None Documented
Terminal elimination half-life: 3-7 hours (mean 4.5 hours). Increased to 8-15 hours in moderate-to-severe renal impairment (CrCl <30 mL/min).
Clinical Note
moderatePhenmetrazine + Atomoxetine
"Phenmetrazine may increase the hypertensive activities of Atomoxetine."
Clinical Note
moderatePhenmetrazine + Iobenguane
"The therapeutic efficacy of Iobenguane can be decreased when used in combination with Phenmetrazine."
Clinical Note
moderatePhenmetrazine + Acebutolol
"The risk or severity of adverse effects can be increased when Phenmetrazine is combined with Acebutolol."
Clinical Note
moderatePhenmetrazine + Isoxsuprine
Terminal elimination half-life is 24-36 hours; increased in renal impairment (up to 60 hours in anuria)
Primarily renal: 70-80% unchanged drug via glomerular filtration and active tubular secretion; 15-20% biliary/fecal as metabolites.
Renal (80-90% as unchanged drug and metabolites), biliary/fecal (10-20%)
Category C
Category C
Antibiotic (Nitroimidazole)
Antibiotic (Nitroimidazole)
"The risk or severity of adverse effects can be increased when Phenmetrazine is combined with Isoxsuprine."